Flyer

Health Science Journal

  • ISSN: 1108-7366
  • Journal h-index: 47
  • Journal CiteScore: 16.17
  • Journal Impact Factor: 2.63
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +441518081309
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • CINAHL Complete
  • Scimago
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • EMCare
  • OCLC- WorldCat
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
Share This Page

Abstract

Case Report: LDAC for the Treatment of Post-Splenectomy Newly Diagnosed PMF Patent with Oral Treatment Inability

Harutyunyan L, Meliksetyan K, Oganesyan A, Oseyan H, Khachatryan H and Hakobyan Y

Primary myelofibrosis (PMF) is a hematologic malignancy belonging to Ph negative myeloproliferative neoplasms (MPN), and it is commonly characterized by a higher risk of acute myeloid leukemia (AML) transformation. The aim of this case report is a demonstration of treatment with low dose cytarabine (LDAC) for a non-transformed newly diagnosed PMF patient with the inability of oral therapy and post-splenectomy complications.